Hip Replacement ArthroplastyCoMNCT02346513
Serum Level of Cobalt and Chromium After Ceramic on Metal Articulation Total Hip Arthroplasty
An observational study of Hip Replacement Arthroplasty, run by Korea University Guro Hospital at 1 site in South Korea.
Trial summary
Primary objectives: 1. To measure serum metal ion levels (blood Chromium (Cr) and Cobalt (Co) ion concentration) in patients that received the Ceramic on Metal arthroplasty of hip and who have well functioning primary total hip arthroplasties during short and medium- term follow up time points. 2. Read more about this study
- Who is it for?
- Ages 20 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Hip Replacement Arthroplasty
- What is being tested?
- Ceramic on Metal Articulation and Non-Ceramic on Metal Articulation
- Type of treatment
- Medical device
- How many people
- 228 participants
- Where
- 1 siteSouth Korea
- Study dates
- Feb 2014to Aug 2015
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The patient population is being drawn for patients seen in the orthopedics department from (April. 2009 -December 2012) patients are selected based on implant type then further selection is based on inclusion and exclusion criteria. Exclusion criteria are specifically selected to exclude any pathologies, or environmental factors that would confound the study population. Once patients are initially selected they are contacted for participation and brought in for screening. Enrollment proceeds until enough patients have been recruited to meet statistical criteria and provide sufficient study power.
Who may be able to join
- Has signed an informed consent to this study approved by the Institutional Review Board
- Is not morbidly obese
- Is clinically qualified for THA based on physical examination and medical history
- Has non inflammatory joint disease( osteoarthritis, traumatic arthritis, avascular necrosis ,pelvic fracture, dysplastic variants)
- Does not have a previous THA or fusion of the hip
- Pre-operative Harris hip score was below 75 scores
Show all 9Show fewer
- Has follow up period that is between 1-2yr or between 2-6yr
- Surgery was performed by minimal invasive posterior approach by the single surgeon in all groups
- Standard postoperative care and rehabilitation protocol for both groups (care providers blinded for implant type/ or not)
Who cannot join
- Diagnosis of inflammatory joint disease
- Any current metal hardware
- Any arthroplasty in any other joint during study follow-up period
- Pre-operative deranged levels of serum urea, creatinine
- Severe medical disability limiting ambulation
- Occupational exposure to cobalt or chromium
Show all 10Show fewer
- If they are taking proprietary multivitamins and minerals
- Chronic steroid or immunosuppressive therapy
- Metabolic bone disease other than osteoporosis
- Has plans to relocate to other geographical area before completion of study
Trial locations and contacts
1 site in 1 country.
South Korea1 site, 1 recruiting
- Recruiting
Korea University Guro Hospital
Seoul, KS013
Won Yong Shon, Professor, +82.10.8908.6681, shonwy@hotmail.com
Tae Wan Kim, Resident, +82.10.3150.3404, hodori44@naver.com
About this study
Primary objectives:
- To measure serum metal ion levels (blood Chromium (Cr) and Cobalt (Co) ion concentration) in patients that received the Ceramic on Metal arthroplasty of hip and who have well functioning primary total hip arthroplasties during short and medium- term follow up time points.
- To compare blood ion levels of patient that received COM arthroplasty with the blood ion levels of patient receiving non-COM standard total hip arthroplasty (a Metal on polyethylene or ceramic on polyethylene total hip arthroplasty) at short- term and medium-term follow up time points .
Read more
Secondary Objective:
- To determine whether these blood levels correlate with any device specific factors such as: component position, size and type, wear rate and/or patient specific factors such as gender, body mass index, age and activity level.
Read the detailed description
Peri-prosthetic osteolysis is associated with aseptic loosening of a total hip replacement (THR). It is understood to be a biological response to wear particles, with polyethylene debris thought to be the major cause of the long-term failure.
With total hip replacement (THR) patients now being younger, more active younger, and anticipating much greater longevity, reduced bearing wear becomes increasingly important. Compared to the wear and osteolysis incidence with metal-polyethylene bearings, the historical results of alternate bearings such as metal-on-metal (MOM) and ceramic-on-ceramic (COC) generally showed much lower wear rates and osteolysis was seemingly quite rare. The laboratory wear-rates for metal-metal bearings have generally fallen into the range 1-7 mm3/million cycles (Mc) and 0.1-1 mm3/Mc for run-in and steady-state phases, respectively.
Ceramic-on-ceramic and metal-on-metal bearing surfaces are often employed for total hip replacement because of their resistance to wear. Alternative bearing surfaces such as ceramic-on-ceramic and metal-on-metal eliminate polyethylene wear. Explanted metal-on-metal articulations made of cobalt-chromium-molybdenum (Co-Cr-Mo) alloy have been shown to have extremely low rates of linear wear, and ceramic-on-ceramic bearings even less. A ceramic-on-ceramic articulation was first implanted in 1970 in France. Long-term reports have shown excellent clinical results.
Ceramic-on-ceramic bearings have the advantage of low wear and high biocompatibility. Alumina-ceramic particles are essentially insoluble in organic media and ionisation is therefore unimportant. However, they have some limits: brittleness is a major concern for ceramic, which could lead to clinically relevant failure rates (0.004% head fracture and 0.22% liner fracture. Although Metal-on-metal (MOM) articulations have been seen as one potential solution to the problems associated with UHMWPE-induced osteolysis, metal ions present in the serum and their potential toxic effects both locally and systemically are a cause for concern.
A low wear rate is believed to be critical for extending the implant life of a prosthetic joint, and wear volumes produced by MOM articulations have been estimated to be 40-100 times lower than metal-on-polyethylene bearings. The wear of MOM prostheses is known to be highly dependent upon the materials, tribological design and finishing technique. Clinical studies of retrieved first and second-generation MOM hip prostheses have shown linear penetrations of approximately 5 μm/year. This is equivalent to a wear volume of approximately 1 mm3/year, two orders of magnitude lower than conventional polyethylene acetabular cups.
The observation that a small number of patients with first-generation MOM prostheses exhibited good clinical and radiographical results after 20 years in vivo led to the development of second-generation MOM hip prostheses, and in 1988 the Metasul prosthesis was introduced into clinical practice. This comprised of a cobalt chrome alloy femoral head articulating on a cobalt chrome alloy acetabular cup. Over 200,000 Metasul combinations have been implanted to date. Short-term clinical performance has been encouraging; with low wear rates, and few prostheses requiring revision. However, long-term clinical performance is as yet unknown.
Although MOM hip prostheses produce significantly lower wear rates than conventional UHMWPE-on-metal couples, and lower wear rates than highly crosslinked UHMWPE-on-metal hip prostheses, there are concerns associated with these bearings. Wear particles have been reported to be in the nanometer size range, an order of magnitude smaller than UHMWPE particles. Therefore, despite a lower wear volume than UHMWPE bearings the number of particles produced are estimated to be greater, possibly between one and ten million particles per step. These small particles have the potential to distribute throughout the body via the lymphatic system, with particles found in the lymph nodes, liver, spleen and bone marrow. As MOM hip prostheses are indicated for younger more active patients these particles will be present at these sites for a long period of time, possibly 30-40 years.
Concern has been expressed about the biological response to metal particles released from metal-on-metal couplings. The levels of cobalt and chromium ions have been measured in the blood and serum in patients with successful THR, but information about the possible release of aluminum from ceramic-on-ceramic articulations is lacking.
A better understanding of the influence of the metallurgy and tribology on wear of the component and improved manufacturing technology have allowed the re-introduction of metal-on-metal articulations in total hip replacement. Excellent early clinical outcome has been reported with the new generation of metal-on-metal components. Retrieval studies of previous metal-on-metal bearings and contemporary implants have shown low rate of wear. These hard bearing surfaces are especially promising for young and active patients. Although metal-on-metal bearings produce significantly less wear debris than metal-on-polyethylene bearing surfaces, the debris generated results in the body being exposed to metal ions for prolonged periods. Concerns exist over metal hypersensitivity, osteolysis, chromosomal mutation, carcinogenicity and fetal exposure to high ion levels. These matters require further investigation, particularly the long-term exposure in younger patients and the recognition that some patients may have unusually high ion levels. From tribological studies, joint simulation testing and clinical trials, it has been proposed that the extent of wear can be reduced by using components with a larger diameter with a high carbon content in the alloy (0.2%), well-adjusted clearance for the components, better implant sphericity and lower surface roughness.
Whilst research has shown that high concentrations of nanometre-sized metal wear particles are cytotoxic to human fibroblasts and macrophages in vitro, there are also concerns about the release of metal ions from these small particles, and the potential effect that these ions have on cells and tissues. Elevated ion concentrations have been reported in both the blood and urine of patients with metallic implant components. In addition, contrary to what might be expected, there is no conclusive evidence that ion levels fall in vivo after the bedding in period of the MOM prostheses, during which wear of the prostheses are higher. Cobalt and chromium ions have high toxicity, and there are very real concerns about the effects of sub-lethal doses of metal ions, which have been shown to cause DNA damage. This damage takes the form of chromosome aberrations and chromosome translocations. Over long periods of exposure the worry is that this will lead to the development of certain types of cancer, such as leukaemia and lymphoma. In animal models elevated levels of cobalt, chromium and nickel have been correlated with increased carcinoma rates. However, reports in the literature of malignancies developing after total hip or knee replacement surgery are exceedingly rare. Out of eight epidemiological studies on the relative risk of cancer after TJR, only one study looked specifically at MOM implants. This study did not find an increased risk of cancer development in the subjects receiving MOM hip prostheses compared to those receiving metal-on-polyethylene hip prostheses. However, all the studies to date have been substantially underpowered in terms of patient numbers required to show a difference between the two prosthesis types.
High levels of cobalt and chromium ions are detected in the blood and urine of patients with metal-on-metal (MOM) hip replacement despite, even with these elements are released as a result of wear at the bearing surfaces. The clinical effects of elevated metal ion levels include local tissue reactions, characterized by increases in T and B cells in the tissues surrounding the hip, and are associated with premature failure of the hip. Systemically, one report suggests reduced numbers of CD8-positive T cells. Metal sensitivity is also a potential problem. Metal ions, whether produced secondary to wear debris or via corrosion can initiate a hypersensitivity response. A delayed cell-mediated response, or delayed-type hypersensitivity response can occur, in which cytokines are released by T-lymphocytes and increased activation of macrophages is seen, which may result in T-cell mediated periprosthetic osteolysis. Many metals can initiate a hypersensitivity response, the most common is nickel followed by cobalt and chromium. Therefore, with the well-documented elevation of cobalt and chromium ions in patients with MOM hip implants, there is a theoretical risk of developing hypersensitivity reactions. Recently, an immune response exclusively associated with second-generation MOM hip prostheses, has been described. Histomorphological changes suggest a type of hypersensitivity reaction to the all-metallic implants. The hypersensitivity hypothesis was further strengthened by the observation that these patients experienced early clinical failure at 11-60 months (mean 29 months), and the fact that patients who received a second MOM prosthesis did not experience any relief of symptoms. Conversely, patients who received either metal-on-polyethylene or ceramic-on-polyethylene couples reported that their symptoms completely disappeared. In a control group of patients with joint prostheses not containing cobalt, chromium or nickel these signs of an immunological reactions were absent. Reports of this type of reaction are becoming increasingly common; however, more research is needed in this area. It is not known whether these patients experience prosthesis failure because of a pre-existing metal sensitivity, or whether metal sensitivity develops because of a high wearing bearing and elevated metal ion levels. Theoretically, there would be an increased probability of developing hypersensitivity to elevated metal ion levels, and hence an increased risk of implant failure.
To reduce the effect of these limitations, such as the breakage of the ceramic insert in COM bearing and to reduce ions release in MOM bearing a hybrid coupling of ceramic-on-metal has been proposed. The theoretical advantage of this new coupling might lead orthopedic surgeons to use it indiscriminately.
- Conditions
- Hip Replacement Arthroplasty
- Being tested
- Ceramic on Metal Articulation, Non-Ceramic on Metal Articulation
- Keywords
- Hip Replacement Arthroplasty, Ceramic on Metal Articulation, Serum level of Cobalt and Chromium
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ceramic on Metal ArticulationDevice
Patients have THA with ceramic on metal articulation
Non-Ceramic on Metal ArticulationDevice
Patients have THA with non-ceramic on metal articulation
| Study group | Role | What they receive |
|---|---|---|
| A: Ceramic on Metal THA | Subgroup A1: Consist of ceramic on metal THAs with short term follow-up (less than 2years)
Subgroup A2: Consist of ceramic on metal THAs with midterm follow-up (more than 2years)
Subgroup A3: Consist of bilateral ceramic on metal THAs Receives: Device: Ceramic on Metal Articulation | |
| B: Non-Ceramic on Metal THA | Patients have THA with non COM bearing Receives: Device: Non-Ceramic on Metal Articulation | |
| C: Healthy subjects | Patients without any implant or systemic disease, to served as controls |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum metal ion analysis
Blood sampling will be performed 2 times during follow-up outpatient clinic visits.
Second sampling is performed 3 months after first sampling.
Measured: 6 months
Secondary outcomes (6)
Wear Measure
A CADD based software POLYWARE (Draftware Inc, CAD viewing and medical image analysis products, Warsaw, Indiana).It is a three-dimensional technique for the measurement of polyethylene wear in metal backed acetabular components. Using a back-lit digitizing tablet, points from AP and Lateral radiographs are captured by AutoCAD software. Custom programming converts the point data into 3D solid models of the prosthesis. The Migration of the Head/cup center points are used to calculate volume displacement.
Measured: 6 months
Radiographic evaluation
Digitalized radiographs of pelvis; standard anteroposterior and lateral oblique radiographs to measure acetabular osteolysis, ante version and abduction angles, a shoot through radiograph to identify impingement and anterior edge loading.
Standard digitalized radiographs taken at 120% (PiView STAR, version5, Infinitt, Seoul, Korea) will be used for analysis of osteolytic lines in peg zones of femoral component as described by Amstutz and Delee and Charnley zones of the acetabular component.
Measured: 6 months
WOMAC score
Clinical evaluation through a questionnaire and physical examination
Measured: 6 months
Harris Hip score
Clinical evaluation through a questionnaire and physical examination
Measured: 6 months
UCLA activity score
Clinical evaluation through a questionnaire and physical examination
Measured: 6 months
Number of Participants with Adverse Events
- Infection
- Hypersensitivity
- Instability
- Impingement
- Fracture
- loosening
- Cardiomyopathy
- Neurological changes including sensory change( auditory or visual impairment)
- Psychological status change( including depression or cognitive impairment,)
- Renal function impairment,
- Thyroid dysfunction
- Noises from the joint(popping, clicking, grinding or squeaking)
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2015 (estimated)
- Study startFeb 2014
- Primary completionMay 2015 (estimated)
- Study completionAug 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hip Replacement ArthroplastyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 228 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Korea University Guro Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Won Yong Shon, Korea University Guro Hospital
- Investigators
- Won Yong Shon, Professor, Principal investigator, Korea University Guro Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02346513
- Sponsor's protocol ID
- MD13036
- Acronym
- CoM
- Status last verified
- Jan 2015
- First submitted
- 24 Nov 2014
- Last updated
- 27 Jan 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jan 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Serum Level of Cobalt and Chromium After Ceramic on Metal Articulation Total Hip Arthroplasty
- ClinicalTrials.gov ID
- NCT02346513
- Acronym / sponsor ID
- CoM / MD13036
- Conditions
- Hip Replacement Arthroplasty
- Keywords
- Hip Replacement Arthroplasty, Ceramic on Metal Articulation, Serum level of Cobalt and Chromium
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 228 participants (estimated)
- Lead sponsor
- Korea University Guro HospitalUniversity, hospital or other
- Study start
- Feb 2014
- Primary completion
- May 2015 (estimated)
- Study completion
- Aug 2015 (estimated)
- First posted
- 27 Jan 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary objectives:
- To measure serum metal ion levels (blood Chromium (Cr) and Cobalt (Co) ion concentration) in patients that received the Ceramic on Metal arthroplasty of hip and who have well functioning primary total hip arthroplasties during short and medium- term follow up time points.
- To compare blood ion levels of patient that received COM arthroplasty with the blood ion levels of patient receiving non-COM standard total hip arthroplasty (a Metal on polyethylene or ceramic on polyethylene total hip arthroplasty) at short- term and medium-term follow up time points .
Secondary Objective:
- To determine whether these blood levels correlate with any device specific factors such as: component position, size and type, wear rate and/or patient specific factors such as gender, body mass index, age and activity level.
Detailed description
Peri-prosthetic osteolysis is associated with aseptic loosening of a total hip replacement (THR). It is understood to be a biological response to wear particles, with polyethylene debris thought to be the major cause of the long-term failure.
With total hip replacement (THR) patients now being younger, more active younger, and anticipating much greater longevity, reduced bearing wear becomes increasingly important. Compared to the wear and osteolysis incidence with metal-polyethylene bearings, the historical results of alternate bearings such as metal-on-metal (MOM) and ceramic-on-ceramic (COC) generally showed much lower wear rates and osteolysis was seemingly quite rare. The laboratory wear-rates for metal-metal bearings have generally fallen into the range 1-7 mm3/million cycles (Mc) and 0.1-1 mm3/Mc for run-in and steady-state phases, respectively.
Ceramic-on-ceramic and metal-on-metal bearing surfaces are often employed for total hip replacement because of their resistance to wear. Alternative bearing surfaces such as ceramic-on-ceramic and metal-on-metal eliminate polyethylene wear. Explanted metal-on-metal articulations made of cobalt-chromium-molybdenum (Co-Cr-Mo) alloy have been shown to have extremely low rates of linear wear, and ceramic-on-ceramic bearings even less. A ceramic-on-ceramic articulation was first implanted in 1970 in France. Long-term reports have shown excellent clinical results.
Ceramic-on-ceramic bearings have the advantage of low wear and high biocompatibility. Alumina-ceramic particles are essentially insoluble in organic media and ionisation is therefore unimportant. However, they have some limits: brittleness is a major concern for ceramic, which could lead to clinically relevant failure rates (0.004% head fracture and 0.22% liner fracture. Although Metal-on-metal (MOM) articulations have been seen as one potential solution to the problems associated with UHMWPE-induced osteolysis, metal ions present in the serum and their potential toxic effects both locally and systemically are a cause for concern.
A low wear rate is believed to be critical for extending the implant life of a prosthetic joint, and wear volumes produced by MOM articulations have been estimated to be 40-100 times lower than metal-on-polyethylene bearings. The wear of MOM prostheses is known to be highly dependent upon the materials, tribological design and finishing technique. Clinical studies of retrieved first and second-generation MOM hip prostheses have shown linear penetrations of approximately 5 μm/year. This is equivalent to a wear volume of approximately 1 mm3/year, two orders of magnitude lower than conventional polyethylene acetabular cups.
The observation that a small number of patients with first-generation MOM prostheses exhibited good clinical and radiographical results after 20 years in vivo led to the development of second-generation MOM hip prostheses, and in 1988 the Metasul prosthesis was introduced into clinical practice. This comprised of a cobalt chrome alloy femoral head articulating on a cobalt chrome alloy acetabular cup. Over 200,000 Metasul combinations have been implanted to date. Short-term clinical performance has been encouraging; with low wear rates, and few prostheses requiring revision. However, long-term clinical performance is as yet unknown.
Although MOM hip prostheses produce significantly lower wear rates than conventional UHMWPE-on-metal couples, and lower wear rates than highly crosslinked UHMWPE-on-metal hip prostheses, there are concerns associated with these bearings. Wear particles have been reported to be in the nanometer size range, an order of magnitude smaller than UHMWPE particles. Therefore, despite a lower wear volume than UHMWPE bearings the number of particles produced are estimated to be greater, possibly between one and ten million particles per step. These small particles have the potential to distribute throughout the body via the lymphatic system, with particles found in the lymph nodes, liver, spleen and bone marrow. As MOM hip prostheses are indicated for younger more active patients these particles will be present at these sites for a long period of time, possibly 30-40 years.
Concern has been expressed about the biological response to metal particles released from metal-on-metal couplings. The levels of cobalt and chromium ions have been measured in the blood and serum in patients with successful THR, but information about the possible release of aluminum from ceramic-on-ceramic articulations is lacking.
A better understanding of the influence of the metallurgy and tribology on wear of the component and improved manufacturing technology have allowed the re-introduction of metal-on-metal articulations in total hip replacement. Excellent early clinical outcome has been reported with the new generation of metal-on-metal components. Retrieval studies of previous metal-on-metal bearings and contemporary implants have shown low rate of wear. These hard bearing surfaces are especially promising for young and active patients. Although metal-on-metal bearings produce significantly less wear debris than metal-on-polyethylene bearing surfaces, the debris generated results in the body being exposed to metal ions for prolonged periods. Concerns exist over metal hypersensitivity, osteolysis, chromosomal mutation, carcinogenicity and fetal exposure to high ion levels. These matters require further investigation, particularly the long-term exposure in younger patients and the recognition that some patients may have unusually high ion levels. From tribological studies, joint simulation testing and clinical trials, it has been proposed that the extent of wear can be reduced by using components with a larger diameter with a high carbon content in the alloy (0.2%), well-adjusted clearance for the components, better implant sphericity and lower surface roughness.
Whilst research has shown that high concentrations of nanometre-sized metal wear particles are cytotoxic to human fibroblasts and macrophages in vitro, there are also concerns about the release of metal ions from these small particles, and the potential effect that these ions have on cells and tissues. Elevated ion concentrations have been reported in both the blood and urine of patients with metallic implant components. In addition, contrary to what might be expected, there is no conclusive evidence that ion levels fall in vivo after the bedding in period of the MOM prostheses, during which wear of the prostheses are higher. Cobalt and chromium ions have high toxicity, and there are very real concerns about the effects of sub-lethal doses of metal ions, which have been shown to cause DNA damage. This damage takes the form of chromosome aberrations and chromosome translocations. Over long periods of exposure the worry is that this will lead to the development of certain types of cancer, such as leukaemia and lymphoma. In animal models elevated levels of cobalt, chromium and nickel have been correlated with increased carcinoma rates. However, reports in the literature of malignancies developing after total hip or knee replacement surgery are exceedingly rare. Out of eight epidemiological studies on the relative risk of cancer after TJR, only one study looked specifically at MOM implants. This study did not find an increased risk of cancer development in the subjects receiving MOM hip prostheses compared to those receiving metal-on-polyethylene hip prostheses. However, all the studies to date have been substantially underpowered in terms of patient numbers required to show a difference between the two prosthesis types.
High levels of cobalt and chromium ions are detected in the blood and urine of patients with metal-on-metal (MOM) hip replacement despite, even with these elements are released as a result of wear at the bearing surfaces. The clinical effects of elevated metal ion levels include local tissue reactions, characterized by increases in T and B cells in the tissues surrounding the hip, and are associated with premature failure of the hip. Systemically, one report suggests reduced numbers of CD8-positive T cells. Metal sensitivity is also a potential problem. Metal ions, whether produced secondary to wear debris or via corrosion can initiate a hypersensitivity response. A delayed cell-mediated response, or delayed-type hypersensitivity response can occur, in which cytokines are released by T-lymphocytes and increased activation of macrophages is seen, which may result in T-cell mediated periprosthetic osteolysis. Many metals can initiate a hypersensitivity response, the most common is nickel followed by cobalt and chromium. Therefore, with the well-documented elevation of cobalt and chromium ions in patients with MOM hip implants, there is a theoretical risk of developing hypersensitivity reactions. Recently, an immune response exclusively associated with second-generation MOM hip prostheses, has been described. Histomorphological changes suggest a type of hypersensitivity reaction to the all-metallic implants. The hypersensitivity hypothesis was further strengthened by the observation that these patients experienced early clinical failure at 11-60 months (mean 29 months), and the fact that patients who received a second MOM prosthesis did not experience any relief of symptoms. Conversely, patients who received either metal-on-polyethylene or ceramic-on-polyethylene couples reported that their symptoms completely disappeared. In a control group of patients with joint prostheses not containing cobalt, chromium or nickel these signs of an immunological reactions were absent. Reports of this type of reaction are becoming increasingly common; however, more research is needed in this area. It is not known whether these patients experience prosthesis failure because of a pre-existing metal sensitivity, or whether metal sensitivity develops because of a high wearing bearing and elevated metal ion levels. Theoretically, there would be an increased probability of developing hypersensitivity to elevated metal ion levels, and hence an increased risk of implant failure.
To reduce the effect of these limitations, such as the breakage of the ceramic insert in COM bearing and to reduce ions release in MOM bearing a hybrid coupling of ceramic-on-metal has been proposed. The theoretical advantage of this new coupling might lead orthopedic surgeons to use it indiscriminately.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 3 Months
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| A: Ceramic on Metal THA | – | Device: Ceramic on Metal ArticulationSubgroup A1: Consist of ceramic on metal THAs with short term follow-up (less than 2years) Subgroup A2: Consist of ceramic on metal THAs with midterm follow-up (more than 2years) Subgroup A3: Consist of bilateral ceramic on metal THAs |
| B: Non-Ceramic on Metal THA | – | Device: Non-Ceramic on Metal ArticulationPatients have THA with non COM bearing |
| C: Healthy subjects | – | –Patients without any implant or systemic disease, to served as controls |
Who may qualify
- Ages
- 20 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The patient population is being drawn for patients seen in the orthopedics department from (April. 2009 -December 2012) patients are selected based on implant type then further selection is based on inclusion and exclusion criteria. Exclusion criteria are specifically selected to exclude any pathologies, or environmental factors that would confound the study population. Once patients are initially selected they are contacted for participation and brought in for screening. Enrollment proceeds until enough patients have been recruited to meet statistical criteria and provide sufficient study power.
Key inclusion criteria (9 listed)
- Has signed an informed consent to this study approved by the Institutional Review Board
- Is not morbidly obese
- Is clinically qualified for THA based on physical examination and medical history
- Has non inflammatory joint disease( osteoarthritis, traumatic arthritis, avascular necrosis ,pelvic fracture, dysplastic variants)
- Does not have a previous THA or fusion of the hip
Key exclusion criteria (10 listed)
- Diagnosis of inflammatory joint disease
- Any current metal hardware
- Any arthroplasty in any other joint during study follow-up period
- Pre-operative deranged levels of serum urea, creatinine
- Severe medical disability limiting ambulation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ceramic on Metal ArticulationPatients have THA with ceramic on metal articulation | Device | A: Ceramic on Metal THA |
| Non-Ceramic on Metal ArticulationPatients have THA with non-ceramic on metal articulation | Device | B: Non-Ceramic on Metal THA |
Primary outcome
Serum metal ion analysis
Time frame: 6 months
Blood sampling will be performed 2 times during follow-up outpatient clinic visits. Second sampling is performed 3 months after first sampling.
6 secondary outcomes
Wear Measure
Time frame: 6 months
Radiographic evaluation
Time frame: 6 months
WOMAC score
Time frame: 6 months
Harris Hip score
Time frame: 6 months
UCLA activity score
Time frame: 6 months
Number of Participants with Adverse Events
Time frame: 6 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jan 2015.
Related trials for Hip Replacement Arthroplasty
Enrolling by invitation
Comparison of Functional Results of ADM X3-MoP Cup (Stryker) and a CoC Cup (Zimmer) in Young Patients
Arthroplasties, Hip Replacement
Not yet recruiting
Total Hip Replacement: an Investigation of Robotic-assisted Versus conVentional Surgery and Patient-centred outcomEs
Osteo Arthritis Knee and Hip
RecruitingObservational study
The restor3d Outcomes Registry
Joint Replacement, Arthropathy
Not yet recruitingObservational study
Preoperative Muscle Stiffness, Functional Reserve, and Postoperative Quality of Recovery in Lower Extremity Arthroplasty
Osteoarthritis (Knee / Hip), Sarcopenia
RecruitingPhase 4
Low-Volume Pericapsular Nerve Group (PENG) Block With Dexamethasone vs Standard-Volume PENG Block After Total Hip Arthroplasty
Pain, Postoperative, Muscle Weakness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Won Yong Shon, Professor principal investigator
Korea University Guro Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hip Replacement Arthroplasty, run by Korea University Guro Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 27 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Won Yong Shon, Professor (+82.10.8908.6681, shonwy@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum metal ion analysis (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2015.